Medigus Announces Proposed Public Offering
Rhea-AI Summary
Medigus Ltd. (NASDAQ:MDGS) announced plans for an underwritten public offering of American Depositary Shares and pre-funded warrants, subject to market conditions. The proceeds will be used for working capital and general corporate purposes. A shelf registration statement has been filed with the SEC, although specifics on the offering size and terms remain uncertain. ThinkEquity is the sole book-running manager. Forward-looking statements caution that completion of the offering is not guaranteed and may be influenced by various risks and uncertainties.
Positive
- Proceeds from the offering intended for working capital and general corporate purposes.
Negative
- Uncertainty regarding the actual size and terms of the offering.
- Forward-looking statements indicate potential risks and market conditions that could affect completion.
News Market Reaction – MDGS
On the day this news was published, MDGS declined 9.56%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
OMER, Israel, May 19, 2020 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that it intends to offer and sell American Depositary Shares and pre-funded warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Medigus intends to use the net proceeds from the proposed offering for working capital and general corporate purposes.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
A shelf registration statement on Form F-3 (File No. 333-238162) relating to the securities to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
Safe Harbor
This press release contains forward-looking statements regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including those risks disclosed in under the caption “Risk Factors” in the preliminary prospectus supplement related to the offering and our Annual Report on Form 20-F filed with the SEC on April 21, 2020 and our other filings with the SEC. Medigus Ltd. cautions readers not to place undue reliance on any forward-looking statements and it does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
About Medigus Ltd.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com.
Contact
Tatiana Yosef
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
FAQ
Who is managing the public offering for Medigus Ltd.?
What risks are associated with Medigus Ltd.'s public offering?
Where can I find more information about the public offering by Medigus Ltd.?
